1447464-73-4
Chemical Structure
IHVR-19029
- CAS No.: 1447464-73-4
- Formula:C23H45N3O5
- Molecular Weight:443.62
IUPAC Name: 3-(tert-butyl)-1-cyclohexyl-1-(6-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)hexyl)urea
InChIKey: GFBNIASMQRMEDU-PLACYPQZSA-N
SMILES: O=C(NC(C)(C)C)N(C1CCCCC1)CCCCCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2
Biological Activity: IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IHVR-19029 | 96.0% | IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bray M, et al. Meeting report: 31st International Conference on Antiviral Research. Antiviral Res. 2018 Oct;158:88-102. [Content Brief]
- [2]. Chang J, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res. 2013;98(3):432‐440. [Content Brief]
- [3]. Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.ACS Med Chem Lett. 2017 Jan 17;8(2):157-162. [Content Brief]
- [4]. Ma J, et al. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Res. 2018 Feb;150:112-122. [Content Brief]
Keywords
